Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | PAX2 | Q02962 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2836561 | 0.85 | MAPT (0.51) | MAPTTSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL3162979 | 0.82 | SLC18A3 (0.57) | MAPTTSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL28188649 | 0.82 | SLC18A3 (0.57) | MAPTTSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL5239265 | 0.81 | NPSR1 (0.58) | MAPTTSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL16727174 | 0.80 | SLC18A3 (0.55) | MAPTTSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL2092264 | 0.79 | MAPT (0.50) | MAPTTSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL13292998 | 0.78 | MEN1 (0.57) | MAPTTSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL4147109 | 0.78 | ALDH1A1 (0.44) | MAPTTSHRALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL3885064 | 0.77 | KMT2A (0.53) | MAPTTSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL29805912 | 0.77 | HTR1A (0.62) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010022055-A2 | INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2010-02-25 | — | — | WO | claimed |
| EP-1865963-A2 | TRIAZADIBENZOAZULENE COMPOUNDS USEFUL FOR THE TREATMENT AND PREVENTION OF PAIN AND SCREENING METHODS THEREFOR | Acadia Pharmaceuticals Inc. (US) | 2007-12-19 | — | — | EP | claimed |
| US-20060217370-A1 | Compounds useful for the treatment and prevention of pain and screening methods therefor | ACADIA PHARMACEUTICALS INC. | 2006-09-28 | — | — | US | claimed |
| WO-2006089286-A2 | TRIAZADIBENZOAZULENE COMPOUNDS USEFUL FOR THE TREATMENT AND PREVENTION OF PAIN AND SCREENING METHODS THEREFOR COMPOUNDS USEFUL FOR THE TREATMENT AND PREVENTION OF PAIN AND SCREENING METHODS THEREFOR | ACADIA PHARMACEUTICALS INC. (US) | 2006-08-24 | — | — | WO | claimed |
| US-6515122-B1 | The invention further relates to combinatorial libraries containing two or more such compounds, as well as methods of preparing tetracyclic benzimidazole derivative compounds. | LION BIOSCIENCE AG (DE) | 2003-02-04 | — | — | US | claimed |
| EP-1218384-A4 | TETRACYCLIC BENZIMIDAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2002-11-20 | — | — | EP | claimed |
| EP-1218384-A1 | TETRACYCLIC BENZIMIDAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | LION Bioscience AG (DE) | 2002-07-03 | — | — | EP | claimed |
| WO-2001023392-A1 | TETRACYCLIC BENZIMIDAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2001-04-05 | — | — | WO | claimed |
| US-10479790-B2 | COMT inhibiting methods and compositions | LIEBER INSTITUTE FOR BRAIN DEVELOPMENT (US) | 2019-11-19 | — | — | US | disclosed |
| US-20180305360-A1 | COMT Inhibiting Methods and Compositions | LIEBER INSTITUTE, INC. | 2018-10-25 | — | — | US | disclosed |
| US-10035799-B2 | COMT inhibiting methods and compositions | LIEBER INSTITUTE FOR BRAIN DEVELOPMENT (US) | 2018-07-31 | — | — | US | disclosed |
| EP-3250209-A1 | COMT INHIBITING METHODS AND COMPOSITIONS | Lieber Institute For Brain Development (US) | 2017-12-06 | — | — | EP | disclosed |
| WO-2016123576-A1 | COMT INHIBITING METHODS AND COMPOSITIONS | LIEBER INSTITUTE FOR BRAIN DEVELOPMENT (US) | 2016-08-04 | — | — | WO | disclosed |
| US-20160222011-A1 | COMT Inhibiting Methods and Compositions | LIEBER INSTITUTE, INC. | 2016-08-04 | — | — | US | disclosed |
| EP-0740649-A1 | NITROXY GROUP-CONTAINING BENZYLAMINE DERIVATIVES AND THEIR USE FOR TREATING CARDIOVASCULAR DISEASES, AS WELL AS INCREASED INTRA-OCULAR PRESSURE | Byk Nederland BV (NL) | 1996-11-06 | — | — | EP | disclosed |
| EP-0731801-A1 | SUBSTITUTED AMINOALKYLAMINOPYRIDINES | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1996-09-18 | — | — | EP | disclosed |
| WO-1996002505-A1 | THIOPYRIDYL COMPOUNDS FOR CONTROLLING HELICOBACTER BACTERIA | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1996-02-01 | — | — | WO | disclosed |
| WO-1996000224-A1 | 4-S- AND N-SUBSTITUTED 6-ALKYLPYRIDINES FOR CONTROLLING HELICOBACTER BACTERIA | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1996-01-04 | — | — | WO | disclosed |
| WO-1995019952-A1 | NITROXY GROUP-CONTAINING BENZYLAMINE DERIVATIVES AND THEIR USE FOR TREATING CARDIOVASCULAR DISEASES, AS WELL AS INCREASED INTRA-OCULAR PRESSURE | BYK NEDERLAND BV (NL) | 1995-07-27 | — | — | WO | disclosed |
| WO-1995015324-A1 | SUBSTITUTED AMINOALKYLAMINOPYRIDINES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1995-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217370-A1 | Compounds useful for the treatment and prevention of pain and screening methods therefor | ACHE, OPRL1, OPRK1 | MAPT 2600/4885TSHR 4277/4885MEN1 4252/4885 |
| US-10035799-B2 | COMT inhibiting methods and compositions | COMT, SLC6A3, MAOA | MAPT 1246/4885TSHR 3707/4885MEN1 4485/4885 |
| US-20160222011-A1 | COMT Inhibiting Methods and Compositions | COMT, SLC6A3, MAOA | MAPT 1246/4885TSHR 3707/4885MEN1 4485/4885 |
| US-20180305360-A1 | COMT Inhibiting Methods and Compositions | COMT, SLC6A3, MAOA | MAPT 1246/4885TSHR 3707/4885MEN1 4485/4885 |
| US-10479790-B2 | COMT inhibiting methods and compositions | COMT, SLC6A3, MAOA | MAPT 1246/4885TSHR 3707/4885MEN1 4485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.